Clinical Trial Update: A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ASP8062 as an add-on to buprenorphine/naloxone for opioid use disorder has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder

Drugs mentioned

• ASP8062
• Buprenorphine/naloxone (buprenorphine/naloxone)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Opioid Use Disorder | Phase 2 | Status: WITHDRAWN